Gene Therapy Market Development Statistics, Research Growth Analysis, and Upcoming Strategies by 2024-2032

Introduction -

Gene therapy, a transformative medical approach, aims to treat or prevent diseases by inserting, altering, or removing genes within an individual's cells. With advancements in biotechnology, the gene therapy market has witnessed substantial growth, driven by innovations in gene editing technologies like CRISPR-Cas9, the increasing prevalence of genetic disorders, and the rising investment in research and development. This overview highlights the key points, trends, and recent industry news in the gene therapy market.

Market Size and Growth -

The Gene Therapy Market is Valued USD 9.42 billion in 2024 and projected to reach USD 38.33 billion by 2030, growing at a CAGR of 22.2% During the Forecast period of 2024-2032. This robust growth is attributed to the increasing approval of gene therapy products, advancements in vector design, and the expanding pipeline of gene therapy candidates.

Download the Sample: https://www.marketdigits.com/request/sample/277

Important Features that are under Offering Gene Therapy Market Highlights of the Reports:

⋆ Detailed Overview of this Market
⋆ Changes in industry market dynamics
⋆ Detailed market segmentation by type, application, etc.
⋆ The historical, current, and projected market size in terms of quantity and value
⋆ Recent industry trends and developments
⋆ Competition situation of this market
⋆ Key companies and product strategies
⋆ Potential niche segment/region showing promising growth.

The list of Key Players Profiled in the study includes:-

Regenxbio, Inc., xford BioMedica plc, Dimension Therapeutics, Inc., Bristol-Myers Squibb Company, SANOFI, Applied Genetic Technologies Corporation, F. Hoffmann-La Roche Ltd, Bluebird Bio, Inc., Novartis AG, Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics), UniQure N.V., Shire Plc, Cellectis S.A., Sangamo Therapeutics, Inc, Orchard Therapeutics, Gilead Lifesciences, Inc., BENITEC BIOPHARMA, Sibiono GeneTech Co., Ltd, Shanghai Sunway Biotech Co., Ltd., Gensight Biologics S.A., Transgene, Calimmune, Inc., Epeius Biotechnologies Corp., Astellas Pharma Inc., American Gene Technologies, BioMarin Pharmaceuticals Inc. and Others

The detailed segments and sub-segment of the market are explained below:

By Technology
• Viral Vector-Based Gene Therapy
• Non-Viral Vectors-Based Gene Therapy
• CRISPR/Cas9 Technology

By Therapy Type
• Acute Lymphoblastic Leukemia (ALL)
• Inherited Retinal Disease
• Large B-Cell Lymphoma
• ADA-SCID
• Melanoma (lesions)
• Beta-Thalassemia Major/SCD
• Head & Neck Squamous Cell Carcinoma
• Peripheral Arterial Disease
• Spinal Muscular Atrophy (SMA)
• Others

By Therapeutic Area
• Oncology
• Neurological Disorders
• Genetic Disorders
• Cardiovascular Disorders
• Ophthalmic Disorders

By End User
• Hospitals and Clinics
• Biopharmaceutical Companies
• Research Institutes

Regions Covered in Market Report:

• North America (United States, Canada, and Mexico)
• Europe (Germany, France, UK, Russia, Italy)
• Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
• South America (Brazil, Argentina, Colombia)
• Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

To Directly Buy This Report @ https://www.marketdigits.com/checkout/277?lic=s

The following are the study objectives for this report:

◘ SWOT Analysis focuses on worldwide main manufacturers to define, assess, and analyze market competition. By kind, application, and region, the market is defined, described, and forecasted.
◘ Examine the global and main regional market potential and advantage, opportunity and challenge, constraints and risks.
◘ Determine whether trends and factors are driving or limiting market growth.
◘ By identifying high-growth categories, stakeholders would be able to analyze market potential.
◘ Conduct a strategic study of each submarket's growth trends and market contribution.
◘ Expansions, agreements, new product launches, and acquisitions in the market are all examples of competitive developments.
◘ To create a strategic profile of the main players and analyze their growth plans in depth.

Key Points -

✦ Therapeutic Areas:

• Genetic Disorders: Gene therapies are primarily developed for rare genetic disorders such as hemophilia, Duchenne muscular dystrophy (DMD), and spinal muscular atrophy (SMA).
• Cancer: Significant progress in gene therapies targeting various cancers, particularly hematological malignancies, is seen with products like CAR-T cell therapies.
• Cardiovascular Diseases: Emerging therapies target conditions like coronary artery disease and heart failure.
• Ophthalmology: Therapies for inherited retinal diseases, such as Luxturna for Leber's congenital amaurosis, are gaining traction.

✦ Technologies and Vectors:

• Viral Vectors: Adeno-associated viruses (AAV) and lentiviruses are commonly used due to their efficiency in delivering therapeutic genes.
• Non-viral Methods: Advancements in nanoparticles and electroporation offer alternatives to viral vectors, potentially reducing immune responses and manufacturing challenges.

✦ Challenges:

• Safety Concerns: Issues like immunogenicity, insertional mutagenesis, and off-target effects remain critical concerns.
• Manufacturing and Scalability: Producing gene therapies at a commercial scale with consistent quality is challenging.
• Cost and Accessibility: High costs of gene therapies, such as Zolgensma ($2.1 million per dose), pose significant accessibility challenges.

We Offer Customized Report, Click @ https://www.marketdigits.com/request/customization/277

Key Trends -

✦ CRISPR and Genome Editing: The adoption of CRISPR-Cas9 and other genome editing technologies is revolutionizing gene therapy development. These tools allow precise gene modifications, enhancing the efficacy and safety of therapies.

✦ Personalized Medicine: Advances in genomics and bioinformatics are enabling the development of personalized gene therapies tailored to individual genetic profiles, improving treatment outcomes.

✦ Collaborations and Partnerships: Increased collaborations between biotech firms, pharmaceutical companies, and academic institutions are driving innovation. Strategic partnerships help leverage expertise, share risks, and accelerate time-to-market.

✦ Expanding Indications: Research is expanding beyond rare genetic disorders to common conditions like cardiovascular diseases, neurodegenerative diseases, and infectious diseases, broadening the potential market.

Recent Industry News -

✦ FDA Approvals: The FDA recently approved several gene therapies, including Zolgensma (for spinal muscular atrophy) and Luxturna (for a rare form of inherited vision loss). These approvals highlight the increasing confidence in the safety and efficacy of gene therapies.

✦ Acquisitions and Investments: The gene therapy sector has seen substantial investment and acquisition activity. In 2022, Bayer acquired Asklepios BioPharmaceutical for $4 billion to strengthen its gene therapy pipeline. Similarly, Novartis' acquisition of AveXis for $8.7 billion underscores the strategic importance of gene therapy in pharmaceutical portfolios.

✦ Clinical Trial Successes: Notable successes in clinical trials have generated optimism in the market. For instance, CRISPR Therapeutics and Vertex Pharmaceuticals reported positive results from their trial of CTX001 for sickle cell disease and beta-thalassemia, marking a significant milestone in gene-editing therapies.

✦ New Partnerships: In 2023, Bluebird Bio entered a strategic partnership with National Resilience, Inc. to enhance the manufacturing and supply chain capabilities for its gene therapies, demonstrating the industry's focus on overcoming production challenges.

✦ Global Expansion: Companies are expanding their presence in emerging markets, particularly in Asia-Pacific. For example, Spark Therapeutics announced plans to establish a gene therapy manufacturing facility in China, aimed at tapping into the growing demand in the region.

Table of Content (TOC):

Chapter 1: Introduction and Overview

Chapter 2: Industry Cost Structure and Economic Impact

Chapter 3: Rising Trends and New Technologies with Major key players

Chapter 4: Global Gene Therapy Market Analysis, Trends, Growth Factor

Chapter 5: Gene Therapy Market Application and Business with Potential Analysis

Chapter 6: Global Market Segment, Type, Application

Chapter 7: Global Gene Therapy Market Analysis (by Application, Type, End User)

Chapter 8: Major Key Vendors Analysis of Gene Therapy Market

Chapter 9: Development Trend of Analysis

Chapter 10: Conclusion

https://www.globenewswire.com/en/news-release/2023/12/06/2791491/0/en/Gene-Therapy-Market-projected-to-reach-USD-38-33-Billion-by-2030-growing-at-a-CAGR-of-22-2-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-recent-study.html

Contact Us:

MarketDigits
1248 CarMia Way Richmond,
VA 23235,
United States.
USA: +1 847 450 0808
Email: sales@marketdigits.com
Web: https://www.marketdigits.com

About MarketDigits:

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

We offer services that are most relevant and beneficial to the users, which help businesses to sustain themselves in this competitive market. Our detailed and in-depth analysis of the markets catering to strategic, tactical, and operational data analysis & reporting needs of various industries utilize advanced technology so that our clients get better insights into the markets and identify lucrative opportunities and areas of incremental revenues.

This release was published on openPR.